Correction: Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids
Guardado en:
Formato: | article |
---|---|
Lenguaje: | EN |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf8fcfc943094f298a06fdeee58923f8 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.
por: Elisa Callegari, et al.
Publicado: (2013) -
The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy
por: Xin Xie, et al.
Publicado: (2022) -
A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition.
por: Neda Bagheri, et al.
Publicado: (2011) -
In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
por: Marie-Claude Bourgeois-Daigneault, et al.
Publicado: (2021) -
Correction: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity
Publicado: (2021)